3.1 Natriuretic Peptides: BNP and NT-proBNP in Clinical Practice

1. Neurohormonal Synthesis and Biochemical Processing

Natriuretic peptides are counter-regulatory neurohormones synthesized primarily by ventricular myocardium in response to increased intracardiac wall tension, volume overload, and elevated transmural filling pressures. Understanding their molecular processing is foundational for clinical interpretation on the Certified Heart Failure Nurse (CHFN) examination.

Gene Expression and Enzymatic Cleavage

Ventricular myocytes continuously transcribe the NPPB gene into the 134-amino-acid precursor pre-proBNP. Removal of an N-terminal signal peptide yields the 108-amino-acid prohormone proBNP₁₋₁₀₈. When ventricular myocytes experience mechanical stretch or hemodynamic stress, proBNP is cleaved in an equimolar (1:1) ratio by intracellular and cell-surface endoproteases, specifically furin and corin, yielding two distinct circulating molecules:

1. B-Type Natriuretic Peptide (BNP): A 32-amino-acid, biologically active C-terminal peptide (proBNP₇₇₋₁₀₈) containing a characteristic 17-amino-acid disulfide ring structure.
2. N-Terminal pro-B-Type Natriuretic Peptide (NT-proBNP): A 76-amino-acid, biologically inert N-terminal peptide fragment (proBNP₁₋₇₆).

Biological Actions of Circulating Active BNP

Biologically active BNP binds to the membrane-bound natriuretic peptide receptor-A (NPR-A) located on vascular smooth muscle, renal tubular epithelium, and adrenal cortical cells. Binding stimulates particulate guanylyl cyclase, generating intracellular cyclic guanosine monophosphate (cGMP). Downstream physiological effects directly counteract the maladaptive hyperactivation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS):

• Vascular Hemodynamics: Balanced systemic arterial and venous vasodilation, reducing both cardiac preload (venous return) and afterload (systemic vascular resistance).
• Renal Tubular Effects: Natriuresis (inhibition of sodium reabsorption in the collecting duct) and osmotic diuresis, accompanied by afferent arteriolar dilation that maintains glomerular filtration.
• Neurohormonal Modulation: Direct suppression of systemic renin release, inhibition of adrenal aldosterone secretion, and central blunting of sympathetic efferent traffic.
• Myocardial Remodeling: Local anti-fibrotic and anti-hypertrophic signaling within cardiac interstitium and myocytes.

---

2. Clearance Mechanisms, Pharmacokinetics, and Half-Life

The physiological divergence between BNP and NT-proBNP determines their diagnostic and serial monitoring characteristics.

Clearance Pathways: NPR-C, Neprilysin, and Glomerular Filtration

Active BNP is cleared actively through two dominant mechanisms:

1. Receptor-Mediated Clearance: Binding to the natriuretic peptide clearance receptor (NPR-C), which internalizes the peptide-receptor complex via endocytosis for lysosomal degradation.
2. Enzymatic Degradation: Cleavage of the 17-amino-acid ring by circulating and membrane-bound neutral endopeptidase (neprilysin / NEP, CD10).
3. Renal Excretion: Only a small fraction of active BNP is eliminated passively by the kidneys.

In contrast, inactive NT-proBNP does not bind NPR-C and is not recognized or cleaved by neprilysin. Instead, NT-proBNP relies almost entirely on passive renal elimination via glomerular filtration. Because NT-proBNP has a significantly longer half-life (70–120 minutes vs. 20 minutes) and depends more heavily on renal clearance, plasma levels of NT-proBNP circulate at concentrations roughly 3 to 6 times higher than BNP under identical hemodynamic conditions, and accumulate dramatically when renal function deteriorates.

---

3. Diagnostic Thresholds in Clinical Practice

In the evaluation of acute undifferentiated dyspnea, natriuretic peptides demonstrate unmatched negative predictive value (> 98%) to rule out heart failure.

Acute Heart Failure Diagnostic Cutoffs

BNP (All Ages):
[  < 100 pg/mL  ] -------- [ 100 to 400 pg/mL ] -------- [  > 400 pg/mL  ]
    RULE OUT                   GRAY ZONE                     RULE IN

NT-proBNP (Universal Rule-Out across all ages: < 300 pg/mL):
Age < 50 yr:     [ < 300 ] ------------------------- [ > 450 pg/mL  ] (Rule In)
Age 50–75 yr:    [ < 300 ] ------------------------- [ > 900 pg/mL  ] (Rule In)
Age > 75 yr:     [ < 300 ] ------------------------- [ > 1800 pg/mL ] (Rule In)

Interpreting BNP Cutoffs

• Rule-Out Cutoff (< 100 pg/mL): Effectively excludes acute decompensated heart failure in dyspneic patients presenting to the emergency department or acute care setting.
• Rule-In Cutoff (> 400 pg/mL): Strongly supports acute decompensated heart failure as the primary cause of symptoms.
• Intermediate Gray Zone (100–400 pg/mL): Represents non-diagnostic intermediate values. Causes include chronic compensated heart failure, mild diastolic dysfunction, cor pulmonale, acute pulmonary embolism, or non-cardiac confounders.

Interpreting NT-proBNP Cutoffs (The ICON Study Criteria)

Because baseline NT-proBNP naturally rises with normal aging due to microvascular stiffening and age-related decline in glomerular filtration rate, a single rule-in threshold is clinically inaccurate. The validated International Collaborative Evaluation of NT-proBNP (ICON) study established a single universal rule-out cutoff paired with three age-stratified rule-in thresholds:

1. Universal Rule-Out (All Ages): < 300 pg/mL rules out acute heart failure with a 99% negative predictive value.
2. Age < 50 years Rule-In: > 450 pg/mL
3. Age 50–75 years Rule-In: > 900 pg/mL
4. Age > 75 years Rule-In: > 1,800 pg/mL

Any NT-proBNP concentration between 300 pg/mL and the patient's age-specific rule-in threshold represents the diagnostic gray zone (e.g., 300–900 pg/mL for a 62-year-old), requiring comprehensive clinical correlation, bedside ultrasound, and echocardiography.

Chronic Ambulatory Heart Failure Cutoffs

In the outpatient setting without acute decompensation, lower baseline thresholds identify structural heart disease (Stage B Pre-Heart Failure) and chronic congestion:

• BNP: ≥ 35 pg/mL
• NT-proBNP: ≥ 125 pg/mL

---

4. Clinical Confounders: False Elevations and False Reductions

Natriuretic peptides are biomarkers of myocardial wall stress, not biomarkers of heart failure etiology. The CHFN nurse must differentiate cardiac wall tension from non-cardiac pathophysiologic confounders.

Causes of Falsely Elevated or Disproportionate Levels

• Renal Impairment (eGFR < 60 mL/min/1.73 m²): Decreased glomerular filtration diminishes clearance of both peptides. NT-proBNP rises more than BNP as filtration falls. Higher rule-in cutoffs have been proposed (for example, NT-proBNP about 1,200 pg/mL when eGFR is <60 mL/min/1.73 m²), and no validated cutoffs exist for patients on dialysis.
• Atrial Fibrillation and Flutter: Persistent atrial tachyarrhythmias cause chronic atrial stretch and electrical remodeling, raising baseline BNP and NT-proBNP concentrations substantially even without ventricular dysfunction.
• Advanced Age: Progressive myocardial fibrosis, arterial stiffening, and subclinical nephron loss cause a steady upward baseline shift.
• Right Ventricular Overload: Acute pulmonary embolism, pulmonary arterial hypertension, and acute cor pulmonale generate significant right ventricular wall stress, triggering peptide release.
• Critical Illness: Severe sepsis, septic shock, systemic inflammatory response syndrome (SIRS), and severe burns cause cytokine-mediated myocardial depression and peptide release.
• Female Sex: Higher endogenous estrogen levels stimulate NPPB promoter transcription, resulting in modestly higher baseline values in women.

Causes of Falsely Reduced or Blunted Levels

• Severe Obesity (BMI ≥ 30 kg/m²): Circulating natriuretic peptide levels are paradoxically reduced by up to 50% in obese individuals compared to normal-weight peers at identical degrees of ventricular filling pressure. Mechanisms include:
  1. Upregulation of adipocyte-expressed clearance receptors (NPR-C), accelerating receptor-mediated degradation.
  2. Enhanced circulating neutral endopeptidase (neprilysin) activity in adipose tissue.
  3. Blunted myocardial peptide transcription secondary to pericardial fat encasement and lipotoxic metabolic signaling. Clinical Consequence: In a morbidly obese patient (BMI ≥ 40 kg/m²), a BNP of 80 pg/mL or an NT-proBNP of 250 pg/mL does not rule out acute pulmonary edema.
• Flash Pulmonary Edema (Hyperacute Onset): When acute severe mitral regurgitation or acute ischemia triggers sudden pulmonary edema within minutes, patient arrival may precede the transcriptional synthesis and secretion of new proBNP, yielding falsely low initial concentrations.
• Constrictive Pericarditis and Mitral Stenosis: Rigid pericardial constriction or severe mitral inflow restriction prevents outward ventricular diastolic expansion, limiting transmural wall stretch and preventing significant peptide elevation.

---

5. Pharmacological Impact of ARNI (Sacubitril/Valsartan)

The introduction of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) has revolutionized heart failure pharmacotherapy while fundamentally altering biomarker interpretation.

Mechanism of Sacubitril-Induced BNP Elevation

Sacubitril is an oral prodrug metabolized by esterases into the active neprilysin inhibitor LBQ657. Neprilysin is the primary enzyme responsible for the metabolic breakdown of active BNP, atrial natriuretic peptide (ANP), bradykinin, and substance P. When neprilysin is pharmacologically inhibited:

1. Active BNP degradation is blocked, leading to a rapid, sustained, and true pharmacological increase in circulating BNP levels.
2. In contrast, NT-proBNP is not a substrate for neprilysin; its clearance is completely unaffected by sacubitril.

The Mandatory Clinical Monitoring Rule

When a patient with heart failure initiates or continues therapy with sacubitril/valsartan:

• BNP becomes harder to interpret: BNP typically rises after ARNI initiation, partly reflecting drug activity rather than clinical decompensation.
• NT-proBNP is the biomarker of choice: As sacubitril/valsartan improves hemodynamics, decreases left ventricular wall stress, and induces reverse remodeling, myocardial synthesis of proBNP declines. Because NT-proBNP clearance is untouched by neprilysin, circulating NT-proBNP levels fall in direct proportion to hemodynamic improvement and decongestion.

Core CHFN Rule: For serial monitoring of a patient receiving an ARNI, use NT-proBNP rather than BNP. The 2022 guideline notes that BNP can rise with neprilysin inhibition while NT-proBNP still tracks wall stress.

---

6. Clinical Case Study and Exam Traps

Clinical Case Scenario

A 68-year-old male with ischemic cardiomyopathy (LVEF 28%, NYHA class III) was initiated on sacubitril/valsartan 24/26 mg twice daily four weeks ago. He presents to the heart failure disease management clinic reporting improved functional tolerance and denied orthopnea or paroxysmal nocturnal dyspnea. Physical exam demonstrates clear breath sounds, jugular venous pressure estimated at 6 cm H₂O, and trace ankle edema. Laboratory testing ordered by the primary care clinic reveals a plasma BNP of 510 pg/mL (baseline prior to ARNI was 280 pg/mL). The covering clinician questions whether the patient is worsening and considers doubling the loop diuretic.

Expert Analysis: The elevation in BNP from 280 to 510 pg/mL is an expected pharmacological consequence of neprilysin inhibition by sacubitril. It does not signify hemodynamic decompensation. The certified heart failure nurse orders an NT-proBNP, which returns at 420 pg/mL (down from a pre-ARNI baseline of 1,450 pg/mL). The 71% decline in NT-proBNP confirms robust hemodynamic decongestion and positive response to ARNI therapy. Increasing diuretics would lead to volume depletion and prerenal azotemia.

Practical Exam Traps and Pitfalls

• The Obesity Trap: Believing that BNP < 100 pg/mL or NT-proBNP < 300 pg/mL eliminates heart failure in a patient with a BMI of 44 kg/m². Remember the 50% suppression rule!
• The ARNI Trap: Believing that NT-proBNP cannot be used in patients taking sacubitril/valsartan. The reverse is true: NT-proBNP is the preferred peptide; BNP is less reliable.
• The Age Trap: Applying the 450 pg/mL or 900 pg/mL cutoff to an 82-year-old patient. For patients over 75 years, the rule-in threshold is strictly > 1,800 pg/mL.
• The Isolated Right Heart Failure Trap: Assuming that right ventricular pressure overload does not elevate natriuretic peptides. Severe RV stretch from pulmonary hypertension or pulmonary embolism significantly elevates both BNP and NT-proBNP.